Piśmiennictwo
1. Pierrot-Deseilligny C, Souberbielle JC. Vitamin D and multiple sclerosis: An update. Mult Scler Relat Disord 2017;14:35-45
2. Looker AC, Pfeiffer CM, Lacher DA, et al. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 2008;88(6):1519-27
3. Bove R, Musallam A, Healy BC, et al. Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler 2014;20(12):1584-92
4. Zhao D, Ouyang P, de Boer IH, et al. Serum vitamin D and sex hormones levels in men and women: The Multi-Ethnic Study of Atherosclerosis (MESA). Maturitas 2017;96:95-102
5. Spanier JA, Nashold FE, Mayne CG, et al. Vitamin D and estrogen synergy in Vdr-expressing CD4(+) T cells is essential to induce Helios(+)FoxP3(+) T cells and prevent autoimmune demyelinating disease. J Neuroimmunol 2015;286:48-58
6. Karaky M, Alcina A, Fedetz M, et al. The multiple sclerosis-associated regulatory variant rs10877013 affects expression of CYP27B1 and VDR under inflammatory or vitamin D stimuli. Mult Scler 2016;22(8):999-1006
7. Ramasamy A, Trabzuni D, Forabosco P, et al. Genetic evidence for a pathogenic role for the vitamin D3 metabolizing enzyme CYP24A1 in multiple sclerosis. Mult Scler Relat Disord 2014;3(2):211-9
8. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476(7359):214-9
9. Graves JS, Barcellos LF, Shao X, et al. Genetic predictors of relapse rate in pediatric MS. Mult Scler 2016;22(12):1528-35
10. Laursen JH, Søndergaard HB, Albrechtsen A, et al. Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis. Mult Scler 2015;21(11):1414-22
11. Ramagopalan SV, Maugeri NJ, Handunnetthi L, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009;5(2):e1000369
12. Nolan D, Castley A, Tschochner M, et al. Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk. Neurology 2012;79(6):538
13. Cocco E, Meloni A, Murru MR, et al. Vitamin D responsive elements within the HLA-DRB1 promoter region in Sardinian multiple sclerosis associated alleles. PLoS One 2012;7(7):e41678
14. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007;61(6):504
15. Ascherio A, Munger KL, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014;71(3):306
16. Kampman MT, Steffensen LH, Mellgren SI, et al. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 2012;18(8):1144
17. Alharbi FM. Update in vitamin D and multiple sclerosis. Neurosciences (Riyadh) 2015;20(4):329
18. Mesliniene S, Ramrattan L, Giddings S, et al. Role of vitamin D in the onset, progression, and severity of multiple sclerosis. Endocr Pract 2013;19(1):129
19. Jagannath VA, Filippini G, Di Pietrantonj C, et al. Vitamin D for the management of multiple sclerosis. Cochrane Database Syst Rev 2018;9(9):CD008422
20. Engkasan JP. Does Vitamin D reduce disease activity in people with multiple sclerosis? A Cochrane Review summary with commentary. NeuroRehabilitation 2019;45(1):135-6
21. De Vincentis S, Russo A, Milazzo M, et al. How Much Vitamin D is Too Much? A Case Report and Review of the Literature. Endocr Metab Immune Disord Drug Targets 2021;21(9):1653-9
22. Kępczyńska K, Zajda M, Lewandowski Z, et al. Bone metabolism and vitamin D status in patients with multiple sclerosis. Neurol Neurochir Pol 2016;50(4):251-7
23. Niedziela N, Pierzchała K, Zalejska-Fiolka J, et al. Assessment of Biochemical and Densitometric Markers of Calcium-Phosphate Metabolism in the Groups of Patients with Multiple Sclerosis Selected due to the Serum Level of Vitamin D3. Biomed Res Int 2018;2018:9329123
24. Huang Z, Qi Y, Du S, et al. BMI levels with MS Bone mineral density levels in adults with multiple sclerosis: a meta-analysis. Int J Neurosci 2015;125(12):904-12
25. Duan S, Lv Z, Fan X, et al. Vitamin D status and the risk of multiple sclerosis: a systematic review and meta-analysis. Neurosci Lett 2014;570:108-13
26. Kubicka K, Pierzchała K. Concentration of 25(OH)D 3 and calcium and phosphorus metabolism in patients suffering from relapsing-remitting multiple sclerosis. A pilot study. Neurol Neurochir Pol 2013;(2):126-30
27. Olsson A, Oturai DB, Sørensen PS, et al. Short-term: high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis. Mult Scler 2015;21(12):1557-65
28. Bazelier MT, van Staa TP, Uitdehaag BM, et al. The risk of fractures in patients with multiple sclerosis: the UK general practice research database. J Bone Miner Res 2011;26(9):2271-9
29. Bazelier MT, van Staa TP, Uitdehaag BM, et al. Risk of fractures in patients with multiple sclerosis. Neurology 2012;78(24):1967-73